The Patent Finder

Medicinal Bioconvergence Research Center

10 patents currently held · Updated Nov 19, 2026
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Aug 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Sep 1, 2027
    The maintenance fee for Method for screening an agent preventing or treating cancer using glycyl-tRNA synthetase and cadherin (US 9,274,113) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
  • 1 fee due Nov 12, 2027
    The maintenance fee for Polypeptide having chemokine activity and uses thereof (US 10,646,547) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 21, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,139,394Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl tRNA synthetase
In force
 · USPTO record
In forceUSPTO record
US 9,435,807Use of leucyl tRNA synthetase
In force
 · USPTO record
In forceUSPTO record
US 10,130,611Use of Benzo-Heterocycle Derivatives for Preventing and Treating Cancer or for Inhibiting Cancer Metastasis
In force
 · High confidence
In forceHigh confidence
US 9,274,113Method for screening an agent preventing or treating cancer using glycyl-tRNA synthetase and cadherin
In force
 · USPTO record
In forceUSPTO record
US 10,258,674Nanoparticles comprising aminoacyl tRNA synthetase and anticancer composition comprising same
In force
 · USPTO record
In forceUSPTO record
US 10,646,547Polypeptide having chemokine activity and uses thereof
In force
 · USPTO record
In forceUSPTO record
US 11,173,192Anti-RNA virus composition comprising EPRS protein or fragment thereof
In force
 · USPTO record
In forceUSPTO record
US 11,518,817Monoclonal antibody specifically binding to MRS
In force
 · USPTO record
In forceUSPTO record
US 11,649,231NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF
In force
 · High confidence
In forceHigh confidence
US 11,561,222Method for Diagnosis of Bile Duct Cancer Using Methionyl-tRNA Synthetase in Bile Duct Cell
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 10: 8 patents in force now held by others · 8 lapsed for an unpaid fee · 4 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 abandoned · 9 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited